The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I expansion of S-222611, a reversible inhibitor of EGFR and HER2, in advanced solid tumors, including patients with brain metastases.
 
Sanjeev Deva
No Relationships to Disclose
 
Richard D. Baird
Consulting or Advisory Role - Shionogi
Research Funding - Shionogi (Inst)
Travel, Accommodations, Expenses - Shionogi
 
Nicola Cresti
Travel, Accommodations, Expenses - IGEA
 
Javier Garcia-Corbacho
Travel, Accommodations, Expenses - Shionogi
 
Linda Hogarth
No Relationships to Disclose
 
Eugene P. Frenkel
No Relationships to Disclose
 
Keiko Kawaguchi
Employment - Shionogi
 
Akinori Arimura
Employment - Shionogi
Stock and Other Ownership Interests - Shionogi
 
Kirsteen Donaldson
Stock and Other Ownership Interests - AstraZeneca; GlaxoSmithKline; Pfizer; Smith & Nephew; Vernalis
Consulting or Advisory Role - Circassia (Inst); Corcept Therapeutics (Inst); Daiichi Sankyo (Inst); Shionogi (Inst); Vernalis (Inst)
 
John Posner
Consulting or Advisory Role - Shionogi
 
Debashis Sarker
Honoraria - Novartis
Consulting or Advisory Role - Lilly; LondonPharma; Novartis
Speakers' Bureau - Pfizer
Travel, Accommodations, Expenses - Bayer; Celgene; Eisai; Lilly; Novartis
 
Duncan Ian Jodrell
Consulting or Advisory Role - Astex Pharmaceuticals
Travel, Accommodations, Expenses - Celgene
 
Ruth Plummer
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Biomarin; Clovis Oncology; GlaxoSmithKline; MSD Oncology; Roche/Genentech; Tesaro; Vertex
Research Funding - AstraZeneca/MedImmune (Inst); Clovis Oncology (Inst); e-Therapeutics (Inst); Eisai (Inst); Ipsen (Inst); Vertex (Inst)
Patents, Royalties, Other Intellectual Property - Named on patent of use of PARP inhibitor rucaparib (Inst)
Travel, Accommodations, Expenses - MSD Oncology; Roche/Genentech
 
James F. Spicer
Honoraria - Boehringer Ingelheim
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Roche Pharma AG; Shionogi